Prominent efficacy from capecitabine mono-therapy for a case with lymphangiosis carcinomatosa derived from recurrent breast cancer

Tadahiro Nozoe; Emiko Mori; Mayuko Kono; Tomohiro Iguchi; Takashi Maeda; Akito Matsukuma; Takahiro Ezaki

Prominent efficacy from capecitabine mono-therapy for a case with lymphangiosis carcinomatosa derived from recurrent breast cancer

Tadahiro Nozoe, Emiko Mori, Mayuko Kono, Tomohiro Iguchi, Takashi Maeda, Akito Matsukuma, Takahiro Ezaki

Faculty of Medical Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

We met a 61-year-old woman who had been suffering from dyspnea due to pleuritis carcinomatosa derived from recurrent breast cancer for which no former chemotherapy had been effective. Capecitabine mono-therapy could exert a drastic anticancer effect for lymphangiosis carcinomatosa causing more severe symptoms of dyspnea. This therapeutic option could be selected for patients with recurrent breast cancer for which the first- or second-line chemotherapy could not provide a sufficient anti-cancer efficacy and possibly serve to sustain the life quality of the patients.

Original language	English
Pages (from-to)	427-429
Number of pages	3
Journal	Japanese Journal of Cancer and Chemotherapy
Volume	38
Issue number	3
Publication status	Published - Mar 15 2011

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{0cc428abdc3f4c41a4189892e4a8a5dd,

title = "Prominent efficacy from capecitabine mono-therapy for a case with lymphangiosis carcinomatosa derived from recurrent breast cancer",

abstract = "We met a 61-year-old woman who had been suffering from dyspnea due to pleuritis carcinomatosa derived from recurrent breast cancer for which no former chemotherapy had been effective. Capecitabine mono-therapy could exert a drastic anticancer effect for lymphangiosis carcinomatosa causing more severe symptoms of dyspnea. This therapeutic option could be selected for patients with recurrent breast cancer for which the first- or second-line chemotherapy could not provide a sufficient anti-cancer efficacy and possibly serve to sustain the life quality of the patients.",

author = "Tadahiro Nozoe and Emiko Mori and Mayuko Kono and Tomohiro Iguchi and Takashi Maeda and Akito Matsukuma and Takahiro Ezaki",

year = "2011",

month = mar,

day = "15",

language = "English",

volume = "38",

pages = "427--429",

journal = "Japanese Journal of Cancer and Chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "3",

}

TY - JOUR

T1 - Prominent efficacy from capecitabine mono-therapy for a case with lymphangiosis carcinomatosa derived from recurrent breast cancer

AU - Nozoe, Tadahiro

AU - Mori, Emiko

AU - Kono, Mayuko

AU - Iguchi, Tomohiro

AU - Maeda, Takashi

AU - Matsukuma, Akito

AU - Ezaki, Takahiro

PY - 2011/3/15

Y1 - 2011/3/15

N2 - We met a 61-year-old woman who had been suffering from dyspnea due to pleuritis carcinomatosa derived from recurrent breast cancer for which no former chemotherapy had been effective. Capecitabine mono-therapy could exert a drastic anticancer effect for lymphangiosis carcinomatosa causing more severe symptoms of dyspnea. This therapeutic option could be selected for patients with recurrent breast cancer for which the first- or second-line chemotherapy could not provide a sufficient anti-cancer efficacy and possibly serve to sustain the life quality of the patients.

AB - We met a 61-year-old woman who had been suffering from dyspnea due to pleuritis carcinomatosa derived from recurrent breast cancer for which no former chemotherapy had been effective. Capecitabine mono-therapy could exert a drastic anticancer effect for lymphangiosis carcinomatosa causing more severe symptoms of dyspnea. This therapeutic option could be selected for patients with recurrent breast cancer for which the first- or second-line chemotherapy could not provide a sufficient anti-cancer efficacy and possibly serve to sustain the life quality of the patients.

UR - http://www.scopus.com/inward/record.url?scp=79957957455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957957455&partnerID=8YFLogxK

M3 - Article

C2 - 21403447

AN - SCOPUS:79957957455

SN - 0385-0684

VL - 38

SP - 427

EP - 429

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

IS - 3

ER -

Prominent efficacy from capecitabine mono-therapy for a case with lymphangiosis carcinomatosa derived from recurrent breast cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Other files and links

Fingerprint

Cite this